What the FDA labels say about taking them together
Dexlansoprazole and tacrolimus
Dexlansoprazole's FDA label of February 17, 2025 names tacrolimus in its drug interactions section; the tacrolimus labels PlainMeds reads (4) do not name dexlansoprazole. The dexlansoprazole label: “Potentially increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.”
Check it at the source: the dexlansoprazole FDA label on DailyMed (effective February 17, 2025, Takeda Pharmaceuticals America, Inc.); the tacrolimus FDA label on DailyMed (effective July 17, 2026, Stellon Biotech Inc.).
What does the dexlansoprazole label say about tacrolimus?
Dexlansoprazole label, drug interactionsTacrolimus Clinical Impact: Potentially increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19. Intervention: Monitor tacrolimus whole blood trough concentrations. Dose adjustment of tacrolimus may be needed to maintain therapeutic drug concentrations. See prescribing information for tacrolimus.
Source: FDA drug label (Dexilant), Takeda Pharmaceuticals America, Inc., effective February 17, 2025 (SPL set 9819f033-3bbe-442e-8e92-45fec77b237d), via openFDA; the full label on DailyMed
What does the tacrolimus label say about dexlansoprazole?
Tacrolimus's label (effective July 17, 2026) and its 3 other brand-application labels do not name dexlansoprazole in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tacrolimus), Stellon Biotech Inc., effective July 17, 2026 (SPL set 6b89e8a4-9f11-42e3-8e79-fe617e7c461f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dexlansoprazole | Tacrolimus | |
|---|---|---|
| Labeled for | Acid reflux and ulcers | Organ transplant rejection, Eczema (atopic dermatitis) |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $3.71 per capsule 60 mg capsule | $0.970 per gram 0.1% ointment |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once